On January 26, 2022, Akili Interactive, which develops digital health technology to treat cognitive impairments, announced it entered into an agreement to become publicly traded via a merger with Social Capital Suvretta Holdings Corp. I (SCS), a special purpose acquisition company (SPAC). The proposed combination has been unanimously approved by the boards of directors of both Akili and SCS and is expected to close in mid-2022. Once the deal closes, Akili will become part of SCS, which is a publicly traded company. After the transaction is complete, Akili intends to launch commercial sales of its flagship product, EndeavorRx® a . . .